C2i Genomics Funding: $112M Raised, Series B (2021)
C2i Genomics is based in New York, NY. It has raised $112M in total funding. Latest round: Series B.
C2i Genomics funding overview
C2i Genomics is based in New York, NY. C2i Genomics has raised $112M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in April 2021. The round record for C2i Genomics runs through 2021; nothing later has been disclosed. Investors on record include Casdin Capital, NFX Capital, The Mark Foundation for Cancer Research. 3 distinct backers are named across the disclosed rounds.
C2i Genomics at a glance
Total raised
$112M
Latest round
Series B
Latest round date
April 2021
Headquarters
New York, NY
Notable investors
Casdin Capital, NFX Capital, The Mark Foundation for Cancer Research
Frequently asked about C2i Genomics funding
How much has C2i Genomics raised?
C2i Genomics has raised $112M in total disclosed funding across the rounds on record.
Who has invested in C2i Genomics?
Casdin Capital, NFX Capital, The Mark Foundation for Cancer Research are named among the investors backing C2i Genomics.
What was the latest C2i Genomics funding round?
The most recent disclosed round is a Series B, announced in April 2021.
Where is C2i Genomics based?
C2i Genomics is based in New York, NY.
When did C2i Genomics last raise?
The last disclosed C2i Genomics round closed in April 2021 at Series B.
Totals shown for C2i Genomics aggregate every disclosed round on file. To see how that compares, browse the companies in New York and the investors behind them below.
